Rocket Pharmaceuticals (RCKT) Equity Average (2015 - 2026)

Rocket Pharmaceuticals has disclosed Equity Average across 12 years of filings, most recently posting $257.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $257.6 million, down 41.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $257.6 million (down 41.14% YoY), and the FY2025 annual result was $370.2 million, down 22.53% from the prior year.
• Equity Average came in at $257.6 million for Q1 2026 at Rocket Pharmaceuticals, down from $295.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $516.8 million in Q4 2023 to a low of $257.6 million in Q1 2026.
• The 5-year median for Equity Average is $413.1 million (2024), against an average of $404.7 million.
• Across the five-year window, Equity Average increased 25.04% in 2023 and sank 41.14% in 2026, its largest moves.
• Rocket Pharmaceuticals' Equity Average stood at $428.5 million in 2022, then gained by 20.61% to $516.8 million in 2023, then fell by 23.28% to $396.5 million in 2024, then slipped by 25.49% to $295.4 million in 2025, then dropped by 12.8% to $257.6 million in 2026.
• The last three Equity Average figures came in at $257.6 million (Q1 2026), $295.4 million (Q4 2025), and $333.9 million (Q3 2025), per Business Quant data.